ArticleJournal of thoracic disease2025
Feasibility and safety of argon plasma coagulation as hemostatic tool during medical thoracoscopy.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medical thoracoscopy (MT) is a minimally invasive procedure used for diagnosing and managing undiagnosed pleural effusions. Argon plasma coagulation (APC) is a non-contact electrosurgical technique widely used in gastrointestinal and bronchoscopic procedures, yet its application in MT remains underreported. This study describes the APC technique during MT for hemostasis and evaluates its safety and feasibility. Methods: We conducted a retrospective observational study of patients who underwent MT with APC at Mayo Clinic, Jacksonville, FL, between December 1, 2022 and April 4, 2024. Patient demographics, procedural details, and pleural fluid analysis were recorded. Hemostasis was achieved using a rigid APC applicator, with bleeding severity assessed using the Validated Intraoperative Bleeding Scale (VIOPS). Descriptive statistical analyses were performed. Results: Twenty patients (median age: 72 years) underwent MT with APC, primarily for recurrent pleural effusion (95%). Adhesiolysis was performed in 60% of cases, and pleural biopsies were obtained in 95%. The median pleural fluid volume removed was 642.5 mL. A single bleeding complication (5%) was recorded (VIOPS score ≥2). No cases of air embolism were observed. Histopathology revealed malignancy in 21.1% of biopsies. Conclusions: MT with APC appears to be a safe and effective technique for achieving hemostasis following pleural biopsy, with a low complication rate. This study provides a foundation for future research on the role of APC in pleuroscopy and its potential advantages over conventional hemostatic techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.